Table 2.
Number of subjects with a positive serologic or Interferon-γ response by treatment group.
| 105 SCAR (N=10) |
107 SCAR (N=10) |
109 SCAR (N=10) |
102 SQ (N=10) |
103 SQ (N=10) |
104 SQ (N=10) |
105 SQ (N=10) |
Placebo (N=14) |
|
|---|---|---|---|---|---|---|---|---|
| Ig A | 3 | 5 | 8* | 1 | 1 | 3 | 2 | 1 |
| IgG | 3 | 7* | 8* | 2 | 1 | 2 | 1 | 0 |
| IgM | 4* | 4* | 6* | 0 | 1 | 4* | 0 | 0 |
| Microagglutination | 3 | 7* | 8* | 2 | 1 | 4* | 1 | 0 |
| Interferon γ | 9* | 8* | 8* | 4 | 2 | 4 | 7* | 2 |
*
P < 0.05 when compared to placebo
Note. A positive serologic response is defined as a fourfold or more rise in antibody levels from baseline when tested at 14, 28, 84 or 180 days post injection. A positive Interferon γ response is defined as a twofold or more rise in tularemia-specific interferon-γ release using a quantiferon assay at 14 or 28 days post injection.